Series B funding round for Prellis Biologics raising $15M in December 2021
Series B funding round for Prellis Biologics raising $15M in December 2021
| Investor | Firm Type | Partner |
|---|
Khosla VenturesLEAD | Venture Capital | — |
Celesta CapitalLEAD | Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Accelerator | — |
| Venture Capital | — |
| Venture Capital | — |
| Angel | Sam Altman |
| Angel | Louis Beryl |
| Angel | Paul Graham |
| Angel | Michael Moritz |
| Angel | Matt Bellamy |
| Angel | Mattia Astori |
| Angel | Sahin Boydas |
| Angel | Alexander Gerko |
This company has completed 7 funding rounds. Current round is highlighted.
Total Raised
$83.1M
Top Valuation
-
Prellis Biologics raised $15M in a Series B round.
The round was announced on 12/01/21.
The round was led by Kevin Chapman, Khosla Ventures.